Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)
BHVN.N on New York Stock Exchange
36.43USD
1:18am IST
36.43USD
1:18am IST
Change (% chg)
$-0.55 (-1.49%)
$-0.55 (-1.49%)
Prev Close
$36.98
$36.98
Open
$36.97
$36.97
Day's High
$37.64
$37.64
Day's Low
$36.41
$36.41
Volume
27,648
27,648
Avg. Vol
165,171
165,171
52-wk High
$44.26
$44.26
52-wk Low
$16.51
$16.51
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Mar '18 | 0.00 | -2.323 |
| FY 2017 | Dec '17 | 0.00 | -0.751 |
| Sep '17 | 0.00 | -1.194 | |
| Jun '17 | 0.00 | -1.784 | |
| Mar '17 | 0.00 | -1.738 | |
| FY 2016 | Dec '16 | 0.00 | -0.499 |
| Sep '16 | 0.00 | -2.119 | |
| Jun '16 | 0.00 | -0.546 | |
| Mar '16 | 0.00 | -0.121 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-18 | 5 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Dec-18 | 5 | 0.00 | 0.00 | 0.00 | 0.00 |
| Year Ending Dec-18 | 7 | 0.00 | 0.00 | 0.00 | 1.32 |
| Year Ending Dec-19 | 7 | 1.90 | 6.17 | 0.00 | 11.94 |
| Earnings (per share) | |||||
| Quarter Ending Sep-18 | 7 | -1.20 | -0.85 | -2.48 | -0.81 |
| Quarter Ending Dec-18 | 7 | -1.20 | -0.82 | -2.31 | -0.82 |
| Year Ending Dec-18 | 7 | -5.80 | -4.83 | -9.48 | -3.76 |
| Year Ending Dec-19 | 7 | -5.00 | -3.01 | -8.97 | -3.99 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
Dividends
Growth Rates
Financial Strength
Profitability Ratios
Efficiency
Management Effectiveness
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -- | -- | -- |
| EPS (TTM) % | -532.85 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Biohaven Pharmaceutical Holding Company Ltd
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Biohaven Initiates Expanded Access Program For Sublingual BHV-0223
- BRIEF-Biohaven Announces Robust Clinical Data With Single Dose Rimegepant That Defines Acute And Durable Benefits To Patients
- Biohaven plunges as investors pit migraine data against Allergan's drug
- Biohaven tumbles as migraine drug efficacy fails to impress investors
- BRIEF-Biohaven Says Achieved Both Co-Primary Regulatory Endpoints In Two Pivotal Phase 3 Trials Of Rimegepant
Institutional Holders
| % Shares Owned: | 74.13% |
| # of Holders: | 140 |
| Total Shares Held: | 28,824,728 |
| 3 Mo. Net Change: | 84,302 |
| # New Positions: | 3 |
| # Closed Positions: | 0 |
| # Increased Positions: | 10 |
| # Reduced Positions: | 2 |
| # Net Buyers: | 8 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.